Abstract
| Original language | English |
|---|---|
| Title of host publication | Patient-Derived Xenograft Models of Human Cancer |
| Editors | Yuzhuo Wang, Dong Lin, Peter W. Gout |
| Publisher | Springer |
| Pages | 11-28 |
| Number of pages | 18 |
| Edition | 1st |
| ISBN (Electronic) | 9783319558257 |
| ISBN (Print) | 9783319558240 |
| DOIs | |
| Publication status | Published - 30 Jun 2017 |
Keywords
- patient-derived xenograft
- tumour graft
- metastasis
- subcutaneous
- renal capsule
- orthotopic
- immunocompromised mice
- prostate cancer
- breast cancer
Cite this
}
Towards best practice in establishing patient-derived xenografts. / Risbridger, Gail P.; Lawrence, Mitchell G.
Patient-Derived Xenograft Models of Human Cancer. ed. / Yuzhuo Wang; Dong Lin; Peter W. Gout. 1st. ed. Springer, 2017. p. 11-28.Research output: Chapter in Book/Report/Conference proceeding › Chapter (Book) › Other › peer-review
TY - CHAP
T1 - Towards best practice in establishing patient-derived xenografts
AU - Risbridger, Gail P.
AU - Lawrence, Mitchell G.
PY - 2017/6/30
Y1 - 2017/6/30
N2 - It is remarkable that human tumour tissues can be grown for months, or even years, as serially transplantable, patient-derived xenografts (PDXs) in immunocompromised mice. The grafting technique used has been refined over the last few decades, so it is now possible to successfully engraft most tumour types, albeit with varying take rates. This review focuses on the methodological requirements to establish successful PDXs. The first step is selecting viable tumour tissue from surgical resections of local or metastatic disease, ascites, pleural effusions, biopsies, circulating tumour cells, rapid autopsies or even organoids. Once grafts are prepared, sometimes with Matrigel or stroma, their likelihood of growing is affected by the strain of immunocompromised host mice and the graft site, which may be subcutaneous, subrenal capsule or orthotopic. Finally, once PDXs are established, authentication assays can be used to rule out possible misidentification or cross-contamination following serial passaging. By carefully optimising all of these steps, PDXs can be grown as efficiently as possible, providing invaluable models for preclinical cancer research.
AB - It is remarkable that human tumour tissues can be grown for months, or even years, as serially transplantable, patient-derived xenografts (PDXs) in immunocompromised mice. The grafting technique used has been refined over the last few decades, so it is now possible to successfully engraft most tumour types, albeit with varying take rates. This review focuses on the methodological requirements to establish successful PDXs. The first step is selecting viable tumour tissue from surgical resections of local or metastatic disease, ascites, pleural effusions, biopsies, circulating tumour cells, rapid autopsies or even organoids. Once grafts are prepared, sometimes with Matrigel or stroma, their likelihood of growing is affected by the strain of immunocompromised host mice and the graft site, which may be subcutaneous, subrenal capsule or orthotopic. Finally, once PDXs are established, authentication assays can be used to rule out possible misidentification or cross-contamination following serial passaging. By carefully optimising all of these steps, PDXs can be grown as efficiently as possible, providing invaluable models for preclinical cancer research.
KW - patient-derived xenograft
KW - tumour graft
KW - metastasis
KW - subcutaneous
KW - renal capsule
KW - orthotopic
KW - immunocompromised mice
KW - prostate cancer
KW - breast cancer
U2 - 10.1007/978-3-319-55825-7_2
DO - 10.1007/978-3-319-55825-7_2
M3 - Chapter (Book)
SN - 9783319558240
SP - 11
EP - 28
BT - Patient-Derived Xenograft Models of Human Cancer
A2 - Wang, Yuzhuo
A2 - Lin, Dong
A2 - Gout, Peter W.
PB - Springer
ER -